Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Viscofan has delivered a modestly positive share price record over the past few years, which puts a spotlight on a simple question. Are investors paying a price that its earnings can reasonably support today, or has the move in the stock got ahead of the underlying profits of the business? Over the past 5 years the stock has returned 15.9%, which makes it important to test whether that outcome lines up with what the current earnings base can justify. The company’s model of producing casings...
AddLife has had a mixed share-price story in recent years, which raises a straightforward question for investors who care about fundamentals. Is the current price around its recent close really aligned with the cash flows the healthcare supplier is expected to generate? Over the past 3 years, AddLife has delivered a very large return of about 216.5%, which puts a lot of weight on whether its cash generation can sustain that kind of re-rating. The business model leans heavily on recurring...
NHK Spring has seen a powerful share price run over the past few years, which naturally raises the question of whether the current ¥3,467 level is backed up by the cash the business can generate. After such a strong stretch, investors are increasingly asking how much of the recent share performance is explained by the company’s underlying cash flows rather than market enthusiasm alone. Over the last 5 years the stock has returned 381.3%. This places significant focus on whether NHK Spring’s...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.